Gastric CancerNCT05124704
Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia
A study testing 5-8ml 0.375% ropivacaine and 5-8ml normal saline in people with Gastric Cancer, run by Wang Jiangling at 1 site in China.
Trial summary
The beneficial of perioperative usage of thoracic epidural anesthesia and analgesia in various thoracic and upper abdominal surgery are well studied. However, intraoperative data are lacking whether combined thoracic epidural and general anesthesia have effect on the median (50%) effective effect-concentration (EC50)… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- 5-8ml 0.375% ropivacaine and 5-8ml normal saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 20 Nov 2021to 25 May 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Gastric cancer patients age between 18-75 yrs;
- ASA physical state I and II
- Undergoing open gastrectomy
Who cannot join
- With contraindications to epidural puncture or catheter placement
- Chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism
- Hepatic, renal, neurological or other organ dysfunctiony
- Younger than 18 years or older than 75 years
- Allergic to local anesthetic solutions or opioids
- Received neo-adjuvant chemotherapy
- Refuse to receive epidural puncture
Trial locations and contacts
1 site in 1 country.
China1 site
Cancer Hospital of the University of Chinese Academy of Sciences
Hangzhou, Zhejiang, 310000
About this study
Official title: Propofol EC50 for Inducing Loss of Consciousness in Gastrectomy: Combined General and Epidural Anesthesia Versus General Anesthesia
The beneficial of perioperative usage of thoracic epidural anesthesia and analgesia in various thoracic and upper abdominal surgery are well studied. However, intraoperative data are lacking whether combined thoracic epidural and general anesthesia have effect on the median (50%) effective effect-concentration (EC50) of propofol for inducing loss of consciousness (LOC). We performed this study among patients undergoing open gastrectomy in gastric cancer patients.
Sixty patients undergoing open gastrectomy were randomly assigned to two groups with thoracic combined general anesthesia (TEA+GA) or general anesthesia (GA) alone. Target-controlled infusion (TCI) of propofol was used for anesthesia induction. The initial propofol concentration of target effect-site (Ceprop) was 3.5 ug/ml and was increased stepwise by 0.5ug/ml at each 4 min intervals by an un-down sequential method to reach LOC. The predicted Ceprop at the time of LOC, intravenous anesthetics, vasopressor requirement, emergency time from anesthesia and postoperative numeric rating scale (NRS) were recorded and analyzed between two groups.
Read the detailed description
After received the approvement of ethics committee of the Cancer Hospital of the University of Chinese Academy of Sciences (approval number IRB- 2021-214). 60 adult gastric cancer patients between 18-75 yrs, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study. The exclusion criteria included: patients with contraindications to epidural puncture or catheter placement; chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism; hepatic, renal, neurological or other organ dysfunction; younger than 18 years or older than 75 years; with allergic to local anesthetic solutions or opioids; received neo-adjuvant chemotherapy; as well as patients who refuse to receive epidural puncture.
Patients were randomly assigned to either TEA+GA group of GA group. The requirement for the modified up-down method was used to confirm sample size (1).
Preoperative arrangements 3-lead electrocardiogram, pulse oximetry and continuously invasive artery blood pressure via left radial artery() were measured for basic monitoring. A central venous catheter was placed in the right internal jugular vein for fluid input and central venous pressure measurement and its position was confirmed by ultrasound. Bispectral Index (BIS) monitor (VT94306, Aspect VISTA, Covidien IIc, MA, USA) was measured for monitoring the depth of anesthetic.
Thoracic Epidural Anesthesia Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted by median approach using "loss-of-resistance"technique and was placed advanced 4 cm cephalad. A test dose of 3ml, 1%, lidocaine was injected through the catheter after the aspiration test for blood and cerebrospinal fluid shows negative results. Non sensory and motor anesthesia after 4 min of test dose injection indicate the absence of accidental subarachnoid placement of the catheter. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, by the second anesthesiologist, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction(2). In group GA, same dose of normal saline was administered before induction and during surgery.
General Anesthesia General anesthesia was induced by propofol plasma target-controlled infusion (TCI) (). To explore the EC50 of propofol for inducing LOC in two groups. We started induction using a series of predicted effect-site concentrations of propofol (Ceprop) with an equal step wise of 0.5 ug/ml, according to the up-down method of Dixon(1). The initial Ceprop for the first patient of each group was 3.5 ug/ml based on previous studies (3) . Positive response to propofol was defined as LOC happened within 4 min after start of TCI under initial concentration. Otherwise the response was taken as negative and propofol concentration was increased 0.5 ug/ml more each 4 min until patient reach LOC (LOC was defined as loss of response to verbal commands). The initial TCI Ceprop was increased by 0.5 ug/ml for the next patients if the previous patient shows negative in the same group. The initial TCI Ceprop was decreased by 0.5 ug/ml for the next patient if the previous patient shows positive in the same group. All the patients were increased by 0.5 ug/ml stepwise at 4 min intervals until they showed LOC. An interval of 4 min was based on the pharmacokinetic and pharmacodynamic (PK-PD) character of propofol in order to obtain the steady-state effect-site concentrations (4; 5). An intravenous of 0.25 mg/Kg oxycodone and 0.6 mg/Kg rocuronium were given after LOC to facilitate tracheal intubation.
Maintenance of anesthesia Anesthesia was maintained with propofol, remifentanil and rocuronium during surgery. Ceprop was adjusted in stepwise of 0.5 ug/ml to keep the BIS between 45 to 55 in two groups. The lowest Ceprop was 2.0 ug/ml to avoid intraoperative awareness. Concentration for remifentanil was between 0.05 ug/Kg/min and 0.25 ug/Kg/ min during surgery depend on the blood pressure. The maintenance doses of rocuronium was 0.15mg/Kg as required to maintain surgical paralysis (6). Patients with hypertension were treated with 10 mg urapidil or 5 mg diltiazem i.v and hypotension was treated initially by speeding Ringger's solution, infusion voluven, then decrease concentration of remifentanil by 0.05 ug/Kg/min until reach the lower limit of 0.05 ug/Kg/min and finally given 5mg ephedrine i.v. 80 ug phenylephrine or 1mg metaraminol were then given if hypotension was remaining.
Postoperative management Anesthetics were stopped when the final surgical suture was done and then 2-4mg/Kg of sugammadex was applied according to the train-of-four (TOF) ratio. The duration between the time of discontinuation of anesthetics and the time of spontaneous opening of eyes was defined as anesthesia emergency time. All patients received postoperative patient-controlled epidural analgesia (PCEA) 0f 0.175% ropivacaine with 0.7ug/ml sufentanil. The PCEA continuous infusion dose was 3-4 ml with patient-controlled bolus dose of 4-5ml depend on the height and weight of patient.
Patients were transferred to PACU after extubation and stay at least 60 min there. In PACU, pain intensity using numerical analogue score of 0-10, postoperative nausea, vomiting and times of hypotension were evaluated and recorded at 30min, 60min and the time leave PACU.
- Conditions
- Gastric Cancer
- Being tested
- 5-8ml 0.375% ropivacaine, 5-8ml normal saline
- Keywords
- Propofol EC50, Epidural anesthesia, Gastric cancer, Gastrectomy
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
5-8ml 0.375% ropivacaineDrug
Also called Experimental
5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
5-8ml normal salineOther
Also called Sham control
5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
| Study group | Role | What they receive |
|---|---|---|
| Combined epidural with general anesthesia | Experimental | Patients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery. Receives: Drug: 5-8ml 0.375% ropivacaine |
| General anesthesia | Sham comparator | In this group, same dose of normal saline was administered before induction and during surgery. Receives: Other: 5-8ml normal saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Propofol EC50 for Inducing Loss of Conciousness
Recording propofol EC50 for inducing loss of conciousness between general with epidural anesthesia group and general group with propofol effect-site target-controlled infusion (TCI) system
Measured: From anesthesia induction to patient loss of consciousness, an average of 5 minutes.
Predicted Effect-site Concentration of Propofol (Ceprop) at Certain Time Points
Recording the effect-site concentration of propofol (Ceprop) which showed on target-controlled infusion (TCI) system at loss of consciousness and discontinuation of anesthetics
Measured: From anesthesia induction to the patient loss of consciousness, an average of 5 minutes.
Secondary outcomes (2)
Anesthetics Consumption
Recording the total propofol and reminfentanil consumption during surgery
Measured: From anesthesia induction to the end of surgery, an average of 2.5 hours.
Postoperative Exhaust Time
Recording the first postoperative exhaust time by daily follow up
Measured: 0-14 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2021
- Study start20 Nov 2021
- Primary completion25 May 2022
- Study completion25 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- 60 adult gastric cancer patients between 18-75 years, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study. Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction. In group GA, same dose of normal saline was administered before induction and during surgery.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wang Jiangling
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Wang Jiangling, Zhejiang Cancer Hospital
- Investigators
- Jiangling Wang, M.D, Principal investigator, Zhejiang Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05124704
- Sponsor's protocol ID
- IRB-2021-214
- Status last verified
- Nov 2024
- First submitted
- 11 Oct 2021
- Last updated
- 9 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Wang J, Shen Y, Guo W, Zhang W, Cui X, Cai S, Chen X. Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study. Front Med (Lausanne). 2023 Nov 6;10:1194077. doi: 10.3389/fmed.2023.1194077. eCollection 2023.
PubMed 38020175
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Propofol EC50 for Inducing Loss of Consciousness in Gastrectomy: Combined General and Epidural Anesthesia Versus General Anesthesia
- ClinicalTrials.gov ID
- NCT05124704
- Acronym / sponsor ID
- IRB-2021-214
- Conditions
- Gastric Cancer
- Keywords
- Propofol EC50, Epidural anesthesia, Gastric cancer, Gastrectomy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Wang JianglingUniversity, hospital or other
- Study start
- 20 Nov 2021 (actual)
- Primary completion
- 25 May 2022 (actual)
- Study completion
- 25 May 2022 (actual)
- First posted
- 18 Nov 2021 (actual)
- Results
- Posted 9 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The beneficial of perioperative usage of thoracic epidural anesthesia and analgesia in various thoracic and upper abdominal surgery are well studied. However, intraoperative data are lacking whether combined thoracic epidural and general anesthesia have effect on the median (50%) effective effect-concentration (EC50) of propofol for inducing loss of consciousness (LOC). We performed this study among patients undergoing open gastrectomy in gastric cancer patients.
Sixty patients undergoing open gastrectomy were randomly assigned to two groups with thoracic combined general anesthesia (TEA+GA) or general anesthesia (GA) alone. Target-controlled infusion (TCI) of propofol was used for anesthesia induction. The initial propofol concentration of target effect-site (Ceprop) was 3.5 ug/ml and was increased stepwise by 0.5ug/ml at each 4 min intervals by an un-down sequential method to reach LOC. The predicted Ceprop at the time of LOC, intravenous anesthetics, vasopressor requirement, emergency time from anesthesia and postoperative numeric rating scale (NRS) were recorded and analyzed between two groups.
Detailed description
After received the approvement of ethics committee of the Cancer Hospital of the University of Chinese Academy of Sciences (approval number IRB- 2021-214). 60 adult gastric cancer patients between 18-75 yrs, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study. The exclusion criteria included: patients with contraindications to epidural puncture or catheter placement; chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism; hepatic, renal, neurological or other organ dysfunction; younger than 18 years or older than 75 years; with allergic to local anesthetic solutions or opioids; received neo-adjuvant chemotherapy; as well as patients who refuse to receive epidural puncture.
Patients were randomly assigned to either TEA+GA group of GA group. The requirement for the modified up-down method was used to confirm sample size (1).
Preoperative arrangements 3-lead electrocardiogram, pulse oximetry and continuously invasive artery blood pressure via left radial artery() were measured for basic monitoring. A central venous catheter was placed in the right internal jugular vein for fluid input and central venous pressure measurement and its position was confirmed by ultrasound. Bispectral Index (BIS) monitor (VT94306, Aspect VISTA, Covidien IIc, MA, USA) was measured for monitoring the depth of anesthetic.
Thoracic Epidural Anesthesia Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted by median approach using "loss-of-resistance"technique and was placed advanced 4 cm cephalad. A test dose of 3ml, 1%, lidocaine was injected through the catheter after the aspiration test for blood and cerebrospinal fluid shows negative results. Non sensory and motor anesthesia after 4 min of test dose injection indicate the absence of accidental subarachnoid placement of the catheter. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, by the second anesthesiologist, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction(2). In group GA, same dose of normal saline was administered before induction and during surgery.
General Anesthesia General anesthesia was induced by propofol plasma target-controlled infusion (TCI) (). To explore the EC50 of propofol for inducing LOC in two groups. We started induction using a series of predicted effect-site concentrations of propofol (Ceprop) with an equal step wise of 0.5 ug/ml, according to the up-down method of Dixon(1). The initial Ceprop for the first patient of each group was 3.5 ug/ml based on previous studies (3) . Positive response to propofol was defined as LOC happened within 4 min after start of TCI under initial concentration. Otherwise the response was taken as negative and propofol concentration was increased 0.5 ug/ml more each 4 min until patient reach LOC (LOC was defined as loss of response to verbal commands). The initial TCI Ceprop was increased by 0.5 ug/ml for the next patients if the previous patient shows negative in the same group. The initial TCI Ceprop was decreased by 0.5 ug/ml for the next patient if the previous patient shows positive in the same group. All the patients were increased by 0.5 ug/ml stepwise at 4 min intervals until they showed LOC. An interval of 4 min was based on the pharmacokinetic and pharmacodynamic (PK-PD) character of propofol in order to obtain the steady-state effect-site concentrations (4; 5). An intravenous of 0.25 mg/Kg oxycodone and 0.6 mg/Kg rocuronium were given after LOC to facilitate tracheal intubation.
Maintenance of anesthesia Anesthesia was maintained with propofol, remifentanil and rocuronium during surgery. Ceprop was adjusted in stepwise of 0.5 ug/ml to keep the BIS between 45 to 55 in two groups. The lowest Ceprop was 2.0 ug/ml to avoid intraoperative awareness. Concentration for remifentanil was between 0.05 ug/Kg/min and 0.25 ug/Kg/ min during surgery depend on the blood pressure. The maintenance doses of rocuronium was 0.15mg/Kg as required to maintain surgical paralysis (6). Patients with hypertension were treated with 10 mg urapidil or 5 mg diltiazem i.v and hypotension was treated initially by speeding Ringger's solution, infusion voluven, then decrease concentration of remifentanil by 0.05 ug/Kg/min until reach the lower limit of 0.05 ug/Kg/min and finally given 5mg ephedrine i.v. 80 ug phenylephrine or 1mg metaraminol were then given if hypotension was remaining.
Postoperative management Anesthetics were stopped when the final surgical suture was done and then 2-4mg/Kg of sugammadex was applied according to the train-of-four (TOF) ratio. The duration between the time of discontinuation of anesthetics and the time of spontaneous opening of eyes was defined as anesthesia emergency time. All patients received postoperative patient-controlled epidural analgesia (PCEA) 0f 0.175% ropivacaine with 0.7ug/ml sufentanil. The PCEA continuous infusion dose was 3-4 ml with patient-controlled bolus dose of 4-5ml depend on the height and weight of patient.
Patients were transferred to PACU after extubation and stay at least 60 min there. In PACU, pain intensity using numerical analogue score of 0-10, postoperative nausea, vomiting and times of hypotension were evaluated and recorded at 30min, 60min and the time leave PACU.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- 60 adult gastric cancer patients between 18-75 years, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study. Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction. In group GA, same dose of normal saline was administered before induction and during surgery.
| Arm | Type | Receives |
|---|---|---|
| Combined epidural with general anesthesia | Experimental | Drug: 5-8ml 0.375% ropivacainePatients in this group received 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction.Followed by a continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction during surgery. |
| General anesthesia | Sham comparator | Other: 5-8ml normal salineIn this group, same dose of normal saline was administered before induction and during surgery. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Gastric cancer patients age between 18-75 yrs;
- ASA physical state I and II
- Undergoing open gastrectomy
Key exclusion criteria (7 listed)
- With contraindications to epidural puncture or catheter placement
- Chronic or acute (within 48 h) intake of psychotropic drugs, benzodiazepines, anticonvulsants, or opioids; alcoholism
- Hepatic, renal, neurological or other organ dysfunctiony
- Younger than 18 years or older than 75 years
- Allergic to local anesthetic solutions or opioids
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 5-8ml 0.375% ropivacaineAlso: Experimental5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery. | Drug | Combined epidural with general anesthesia |
| 5-8ml normal salineAlso: Sham control5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery. | Other | General anesthesia |
Primary outcome
Propofol EC50 for Inducing Loss of Conciousness
Time frame: From anesthesia induction to patient loss of consciousness, an average of 5 minutes.
Recording propofol EC50 for inducing loss of conciousness between general with epidural anesthesia group and general group with propofol effect-site target-controlled infusion (TCI) system
Predicted Effect-site Concentration of Propofol (Ceprop) at Certain Time Points
Time frame: From anesthesia induction to the patient loss of consciousness, an average of 5 minutes.
Recording the effect-site concentration of propofol (Ceprop) which showed on target-controlled infusion (TCI) system at loss of consciousness and discontinuation of anesthetics
2 secondary outcomes
Anesthetics Consumption
Time frame: From anesthesia induction to the end of surgery, an average of 2.5 hours.
Postoperative Exhaust Time
Time frame: 0-14 days postoperatively
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38020175Wang J, Shen Y, Guo W, Zhang W, Cui X, Cai S, Chen X. Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study. Front Med (Lausanne). 2023 Nov 6;10:1194077. doi: 10.3389/fmed.2023.1194077. eCollection 2023.
- Individual participant dataSharing planned: No
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jiangling Wang, M.D principal investigator
Zhejiang Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 5-8ml 0.375% ropivacaine and 5-8ml normal saline in people with Gastric Cancer, run by Wang Jiangling at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Propofol EC50 for Inducing Loss of Conciousness (time frame: From anesthesia induction to patient loss of consciousness, an average of 5 minutes.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05124704, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2025.